Altered lipoprotein metabolism in P2Y13 knockout mice

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 12, 2010, Pages 1349-1360

  Blom, Daniël ^a   Yamin, Ting ting ^a   Champy, Marie France ^b   Selloum, Mohammed ^b   Bedu, Elodie ^b   Carballo Jane, Ester ^a   Gerckens, Lynn ^a   Luell, Silvi ^a   Meurer, Roger ^a   Chin, Jayne ^a   Mudgett, John ^a   Puig, Oscar ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

Gene expression profiling; GPR86; HDL; P2ry13; Reverse Cholesterol Transport; SREBP

Indexed keywords

HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; PURINERGIC P2Y13 RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; CHOLESTEROL TRANSPORT; FATTY ACID SYNTHESIS; FEMALE; GENE EXPRESSION; GLUCOSE TOLERANCE; IN VIVO STUDY; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEROID METABOLISM;

ANIMALS; FEMALE; GENE EXPRESSION PROFILING; LIPOPROTEINS; LIVER; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, PURINERGIC P2; RNA, MESSENGER;

MUS;

EID: 77957943566     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.08.013     Document Type: Article

References (30)

1. Francis G.A., Perry R.J. Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis. Clin. Chim. Acta 1999, 286:219-230.
2. Toth P.P., Davidson M.H. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr. Opin. Cardiol. 2004, 19:374-379.
3. Lewis G.F., Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 2005, 96:1221-1232.
4. Lewis G.F. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr. Opin. Cardiol. 2006, 21:345-352.
5. Zhang Y., Ahmed A.M., Tran T.L., Lin J., McFarlane N., Boreham D.R., Igdoura S.A., Truant R., Trigatti B.L. The inhibition of endocytosis affects HDL-lipid uptake mediated by the human scavenger receptor class B type I. Mol. Membr. Biol. 2007, 24:442-454.
6. Pagler T.A., Rhode S., Neuhofer A., Laggner H., Strobl W., Hinterndorfer C., Volf I., Pavelka M., Eckhardt E.R., van der Westhuyzen D.R., Schutz G.J., Stangl H. SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux. J. Biol. Chem. 2006, 281:11193-11204.
7. Silver D.L., Wang N., Xiao X., Tall A.R. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J. Biol. Chem. 2001, 276:25287-25293.
8. Rinninger F., Brundert M., Brosch I., Donarski N., Budzinski R.M., Greten H. Lipoprotein lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent of scavenger receptor BI. J. Lipid Res. 2001, 42:1740-1751.
9. Brundert M., Heeren J., Greten H., Rinninger F. Hepatic lipase mediates an increase in selective uptake of HDL-associated cholesteryl esters by cells in culture independent from SR-BI. J. Lipid Res. 2003, 44:1020-1032.
10. Martinez L.O., Jacquet S., Esteve J.P., Rolland C., Cabezon E., Champagne E., Pineau T., Georgeaud V., Walker J.E., Terce F., Collet X., Perret B., Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003, 421:75-79.
11. Morrison J.R., McPherson G.A., Fidge N.H. Evidence for two sites on rat liver plasma membranes which interact with high density lipoprotein. J. Biol. Chem. 1992, 267:13205-13209.
12. Barbaras R., Collet X., Chap H., Perret B. Specific binding of free apolipoprotein A-I to a high-affinity binding site on HepG2 cells: characterization of two high-density lipoprotein sites. Biochemistry 1994, 33:2335-2340.
13. Jacquet S., Malaval C., Martinez L.O., Sak K., Rolland C., Perez C., Nauze M., Champagne E., Terce F., Gachet C., Perret B., Collet X., Boeynaems J.M., Barbaras R. The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell. Mol. Life Sci. 2005, 62:2508-2515.
14. Communi D., Gonzalez N.S., Detheux M., Brezillon S., Lannoy V., Parmentier M., Boeynaems J.M. Identification of a novel human ADP receptor coupled to G(i). J. Biol. Chem. 2001, 276:41479-41485.
15. Wittenberger T., Schaller H.C., Hellebrand S. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. J. Mol. Biol. 2001, 307:799-813.
16. Lee D.K., Nguyen T., Lynch K.R., Cheng R., Vanti W.B., Arkhitko O., Lewis T., Evans J.F., George S.R., O'Dowd B.F. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene 2001, 275:83-91.
17. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31:e15.
18. Greco D., Leo D., di Porzio U., Perrone Capano C., Auvinen P. Pre-filtering improves reliability of Affymetrix GeneChips results when used to analyze gene expression in complex tissues. Mol. Cell. Probes 2008, 22:115-121.
19. Van Berkel T.J., Van Velzen A., Kruijt J.K., Suzuki H., Kodama T. Uptake and catabolism of modified LDL in scavenger-receptor class A type I/II knock-out mice. Biochem. J. 1998, 331(Pt 1):29-35.
20. Schadt E.E., Molony C., Chudin E., Hao K., Yang X., Lum P.Y., Kasarskis A., Zhang B., Wang S., Suver C., Zhu J., Millstein J., Sieberts S., Lamb J., GuhaThakurta D., Derry J., Storey J.D., Avila-Campillo I., Kruger M.J., Johnson J.M., Rohl C.A., van Nas A., Mehrabian M., Drake T.A., Lusis A.J., Smith R.C., Guengerich F.P., Strom S.C., Schuetz E., Rushmore T.H., Ulrich R. Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 2008, 6:e107.
21. Chen Y., Zhu J., Lum P.Y., Yang X., Pinto S., MacNeil D.J., Zhang C., Lamb J., Edwards S., Sieberts S.K., Leonardson A., Castellini L.W., Wang S., Champy M.F., Zhang B., Emilsson V., Doss S., Ghazalpour A., Horvath S., Drake T.A., Lusis A.J., Schadt E.E. Variations in DNA elucidate molecular networks that cause disease. Nature 2008, 452:429-435.
22. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., Goldstein J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl Acad. Sci. USA 2003, 100:12027-12032.
23. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68:879-887.
24. Berger J.P., Akiyama T.E., Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 2005, 26:244-251.
25. Plutzky J. Peroxisome proliferator-activated receptors as therapeutic targets in inflammation. J. Am. Coll. Cardiol. 2003, 42:1764-1766.
26. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
27. Kersten S., Seydoux J., Peters J.M., Gonzalez F.J., Desvergne B., Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 1999, 103:1489-1498.
28. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.C., Staels B., Auwerx J. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J. Clin. Invest. 1995, 96:741-750.
29. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 1995, 95:705-712.
30. Marteau F., Le Poul E., Communi D., Labouret C., Savi P., Boeynaems J.M., Gonzalez N.S. Pharmacological characterization of the human P2Y13 receptor. Mol. Pharmacol. 2003, 64:104-112.